Artigos relacionados
Câncer de pulmão de pequenas células
Aggressive lung cancer with low five-year survival, focus of the DeLLphi-305 trial combining tarlatamab and durvalumab.
Artigos relacionados
Aggressive lung cancer with low five-year survival, focus of the DeLLphi-305 trial combining tarlatamab and durvalumab.